STOCK TITAN

TransMedics to Report Third Quarter 2025 Financial Results on October 29, 2025

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

TransMedics (Nasdaq:TMDX) will report third quarter 2025 financial results after market close on Wednesday, October 29, 2025.

The TransMedics management team will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT; domestic dial-in is (844) 676-6010 and international dial-in is (412) 634-6944. A live and archived webcast will be available in the Investors section at https://investors.transmedics.com/.

TransMedics (Nasdaq:TMDX) riferirà i risultati finanziari del terzo trimestre 2025 dopo la chiusura del mercato di mercoledì 29 ottobre 2025.

Il team di gestione di TransMedics terrà una conference call alle 16:30 ET / 13:30 PT; la linea nazionale è (844) 676-6010 e la linea internazionale è (412) 634-6944. Una webcast in diretta e archiviata sarà disponibile nella sezione Investors all'indirizzo https://investors.transmedics.com/.

TransMedics (Nasdaq:TMDX) reportará los resultados financieros del tercer trimestre de 2025 después del cierre del mercado el miércoles 29 de octubre de 2025.

El equipo directivo de TransMedics organizará una conferencia telefónica a las 4:30 p.m. ET / 1:30 p.m. PT; la marcación nacional es (844) 676-6010 y la marcación internacional es (412) 634-6944. Una transmisión en vivo y una grabación estarán disponibles en la sección Inversores en https://investors.transmedics.com/.

TransMedics (Nasdaq:TMDX)2025년 3분기 재무 실적을 2025년 10월 29일 수요일 장 마감 후 발표합니다.

TransMedics 경영진은 동부 표준시 16:30 / 태평양 표준시 13:30에 컨퍼런스 콜을 주최합니다; 국내 다이얼인 번호는 (844) 676-6010, 국제 다이얼인은 (412) 634-6944입니다. 라이브 및 보관용 웹캐스트는 투자자 섹션에서 이용할 수 있으며 공식 웹사이트는 https://investors.transmedics.com/입니다.

TransMedics (Nasdaq:TMDX) publiera les résultats financiers du troisième trimestre 2025 après la clôture du marché le mercredi 29 octobre 2025.

L'équipe de direction de TransMedics animera une conférence téléphonique à 16 h 30 HE / 13 h 30 HP ; le numéro national est (844) 676-6010 et le numéro international est (412) 634-6944. Une webdiffusion en direct et archivée sera disponible dans la section Investisseurs à l'adresse https://investors.transmedics.com/.

TransMedics (Nasdaq:TMDX) wird die Ergebnisse des dritten Quartals 2025 nach Börsenschluss am Mittwoch, dem 29. Oktober 2025 bekannt geben.

Das Management-Team von TransMedics wird einen Conference Call um 16:30 Uhr ET / 13:30 Uhr PT abhalten; telefonisch im Inland erreichbar unter (844) 676-6010 und international unter (412) 634-6944. Ein Live- und Archiv-Webcast ist im Abschnitt Investoren unter https://investors.transmedics.com/ verfügbar.

TransMedics (Nasdaq:TMDX) ستعلن عن نتائجها المالية للربع الثالث من عام 2025 بعد إغلاق السوق يوم الأربعاء 29 أكتوبر 2025.

سيعقد فريق إدارة TransMedics مكالمة مؤتمرات في الساعة 4:30 م بتوقيت شرق الولايات المتحدة / 1:30 م بتوقيت المحيط الهادئ؛ الرقم المحلي للمداخلات هو (844) 676-6010 والرقم الدولي هو (412) 634-6944. سيكون هناك بث حي ومراجعة محفوظة عبر الويب في قسم المستثمرون على العنوان https://investors.transmedics.com/.

TransMedics (纳斯达克:TMDX) 将于2025年第三季度财报在市场收盘后公布,时间为2025年10月29日星期三

TransMedics管理层将于东部时间16:30 / 太平洋时间13:30举行电话会议;国内拨号为(844) 676-6010,国际拨号为(412) 634-6944。现场直播及存档的网络广播将在投资者板块的https://investors.transmedics.com/上提供。

Positive
  • None.
Negative
  • None.

ANDOVER, Mass., Oct. 15, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2025 after market close on Wednesday, October 29, 2025. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.

Investors interested in listening to the conference call may do so by dialing (844) 676-6010 for domestic callers or (412) 634-6944 for international callers and ask to be joined into the TransMedics call. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/.   

About TransMedics Group, Inc.

TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Investor Contact:
Brian Johnston
Laine Morgan
332-895-3222
Investors@transmedics.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-to-report-third-quarter-2025-financial-results-on-october-29-2025-302585122.html

SOURCE TransMedics Group, Inc.

FAQ

When will TransMedics (TMDX) release third quarter 2025 results?

TransMedics will release third quarter 2025 results after market close on October 29, 2025.

What time is the TransMedics (TMDX) Q3 2025 earnings call?

The management call begins at 4:30 p.m. ET / 1:30 p.m. PT on the release date.

How can I join the TransMedics (TMDX) conference call on October 29, 2025?

Dial (844) 676-6010 (domestic) or (412) 634-6944 (international) and ask to be joined into the TransMedics call.

Where will the TransMedics (TMDX) webcast be available?

A live and archived webcast will be available in the Investors section at https://investors.transmedics.com/.

Will the TransMedics (TMDX) Q3 2025 webcast be archived for later viewing?

Yes. The company will provide an archived webcast in the Investors section of its website.

Are there separate dial-in numbers for domestic and international callers for the TransMedics call?

Yes. Domestic callers use (844) 676-6010; international callers use (412) 634-6944.
Transmedics Group

NASDAQ:TMDX

TMDX Rankings

TMDX Latest News

TMDX Latest SEC Filings

TMDX Stock Data

3.79B
33.08M
3.01%
111.49%
24.26%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
ANDOVER